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Abstract
Purpose—Long-term follow-up of newborn screening for conditions such as sickle cell disease 
can be conducted using linkages to population-based data. We sought to estimate childhood sickle 
cell disease mortality and risk factors among a statewide birth cohort with sickle cell disease 
identified through newborn screening.
Methods—Children with sickle cell disease identified by newborn screening and born to New 
York residents in 2000–2008 were matched to birth and death certificates. Mortality rates were 
calculated (using numbers of deaths and observed person-years at risk) and compared with 
mortality rates for all New York children by maternal race/ethnicity. Stratified analyses were 
conducted to examine associations between selected factors and mortality.
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Results—Among 1,911 infants with sickle cell disease matched to birth certificates, 21 deaths 
were identified. All-cause mortality following diagnosis was 3.8 per 1,000 person-years in the first 
2 years of life and 1.0 per 1,000 person-years at ages 2–9 years. The mortality rate was 
significantly lower among children of foreign-born mothers and was significantly higher among 
preterm infants with low birth weight. The mortality rates were not significantly higher for infants 
after 28 days with sickle cell disease than for all New York births, but they were 2.7–8.4 times 
higher for children 1 through 9 years old with homozygous sickle cell disease than for those of all 
non-Hispanic black or Hispanic children born to New York residents.
Conclusion—Estimated mortality risk in children with homozygous sickle cell disease remains 
elevated even after adjustment for maternal race/ethnicity. These results provide evidence 
regarding the current burden of child mortality among children with sickle cell disease despite 
newborn screening.
Keywords
long-term follow-up; maternal race/ethnicity; mortality; newborn screening; sickle cell disease
INTRODUCTION
In the United States, 80,000–100,000 people, primarily of African ancestry, have sickle cell 
disease (SCD).1–3 Based on national newborn screening (NBS) records, the frequency of 
SCD is ~1 in 360 live births among African Americans and 1 in 16,300 live births among 
Hispanics.4 In New York, the estimated incidence is 1 in 230 newborns born to non-
Hispanic black mothers and 1 in 2,320 newborns born to Hispanic mothers.5
People with SCD are at risk of life-threatening complications and organ damage, reducing 
quality of life and life expectancy.4,6 Before the 1980s, mortality among US children with 
SCD was high primarily due to infections.7 Median age at death attributed to sickle cell 
anemia in 1967 was roughly 20 years.8 Subsequent improvements in life span and reduced 
childhood mortality9–16 reflect multiple interventions, including early diagnosis by 
NBS,17–19 parental education,20 and standardized preventive and therapeutic approaches, in 
particular penicillin prophylaxis,21 hydroxyurea,22–24 and pneumococcal immunization.25
Long-term follow-up (LTFU) of children with inherited disorders identified by NBS is 
essential to ensure the timely receipt of disease-modifying interventions in a medical home 
and to track the health status and health-care utilization of affected children.26 The Centers 
for Disease Control and Prevention funded four states to conduct LTFU through 3 years of 
age for children with metabolic disorders detected through NBS.27 Various methods have 
been used to collect and analyze data on health-care utilization and health outcomes for 
children identified through NBS.27,28 Studies showed that the use of linked population-
based administrative data sources is a feasible and relatively inexpensive method to conduct 
LTFU.28,29
In 2010, the New York State Department of Health and six other state health departments 
were awarded funds by the Centers for Disease Control and Prevention and the National 
Heart, Lung and Blood Institute/National Institutes of Health to develop a pilot population-
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based statewide surveillance system for SCD and thalassemia.30 The objectives of this study 
were to conduct LTFU of children with SCD identified through NBS by linking the children 




The study cohort contains children with confirmed diagnoses of SCD—identified by the 
New York State Department of Health NBS program31—born to New York residents in 
2000–2008. SCD types included hemoglobin S disease (HbSS), sickle–hemoglobin C 
disease (HbSC), sickle β0 thalassemia (HbSβ0), sickle β+ thalassemia, and other less 
common forms of SCD. DNA testing is not performed by the NBS program, and hence the 
children with HbSS cannot be definitively distinguished from those with HbSβ0. More than 
96% of cases of SCD in New York involved HbSS, HbSβ0, or HbSC. Children born outside 
of New York were not included in this analysis.
Vital records
The Bureau of Biometrics and Health Statistics of the New York State Department of Health 
and the Office of Vital Statistics of the New York City Department of Health and Mental 
Hygiene provided birth and death certificate data for New York residents following approval 
by the institutional review boards of both agencies. Birth certificates include clinical data 
(birth weight and gestational age) and demographic data (maternal race/ ethnicity and 
country of birth); death certificates include the child’s age and cause of death.
Data matching
The SCD cases were matched to birth records to obtain demographic and clinical 
information; the SCD cases were matched to death records to identify deaths, using 
deterministic data linkage methods, as described elsewhere.5
Deaths
Deaths among the study cohort during the years 2000–2009 were ascertained from the death 
certificates. The longest follow-up period was 10 years, for children born in 2000, whereas 
the shortest follow-up period was 1 year, for those born in 2008. Date of death and causes of 
death were obtained from death certificates. Deaths were presumed to be related to SCD if 
an SCD diagnosis (International Classification of Diseases, 10th revision, codes D57.0, 
D57.1, D57.2, D57.4, or D57.8) was listed on the death certificate and no unrelated cause of 
death was listed. Records were reviewed by two coauthors (N.S.G., S.D.G.), who followed a 
similar approach used in a previous study to categorize deaths as potentially related to SCD 
or unrelated to SCD. The coauthors classified deaths with perinatal conditions, birth defects, 
autoimmune disorders, or other causes not associated with the clinical course of SCD as 
unrelated to SCD.13 The primary and secondary causes of death for children born with SCD 
but for whom SCD was not listed on the death certificate were similarly reviewed.
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Mortality rate was calculated as the number of deaths divided by total person-years at risk. 
Person-years at risk were calculated using date of birth and date of death for deceased cases. 
For children who were alive at the end of the study, person-years at risk were calculated 
using date of birth and the end date of the study (31 December 2009). Mortality rates were 
calculated by SCD type and by selected demographic and clinical risk factors, including the 
child’s sex, birth weight, and gestational age, as well as maternal age, race/ethnicity, country 
of birth, and residence at delivery (either New York City or New York State excluding New 
York City).
To compare child (≤9 years old) mortality for children with SCD and all live births (with or 
without SCD), the ratios of mortality rates were calculated after excluding deaths during the 
first 28 days of life. The comparative analysis excluded neonatal (<28 days) deaths because 
deaths of infants with SCD who died before the collection of dried blood spots or before the 
infant completed the screening and diagnostic process were not included among SCD 
deaths. Owing to limited access to vital records for the study period, we were not able to 
match all live births in 2000–2008 to the death certificate files to estimate the mortality rate 
restricted to children born without SCD.
The Poisson exact test for modeling rare events with person–time data was used to examine 
the relative risk (mortality rate ratio) and 95% confidence interval for selected demographic 
factors. A P value <0.05 was chosen to indicate that the mortality rates between comparison 
groups are statistically significantly different; no adjustment was made for multiple 
comparisons. The SAS software package, version 9.2 (SAS Institute, Cary, NC) was used 
for summary statistics and regression analysis.
RESULTS
A total of 1,911 newborns with SCD identified through NBS were matched to birth 
certificates from among ~2.2 million New York live births during the years 2000–2008. 
Twenty-one deaths (1.1%) subsequent to a diagnosis of SCD were identified during the 
follow-up period of 2000–2009. The numbers of SCD cases, deaths, person-years at risk, 
mortality rates, and median age at death by selected demographic and clinical factors and by 
age group are presented in Table 1. The overall mortality rate was 2.0 per 1,000 person-
years for all SCD cases, 2.5 per 1,000 for HbSS and HbSβ0 cases, and 1.4 per 1,000 person-
years for HbSC cases. No deaths were found among children with other types of SCD. 
Statistically significantly higher overall mortality rates were found among low–birth-weight 
(LBW) children compared with normal-birth-weight children (5.5 vs. 1.6 per 1,000 person-
years; P = 0.02) and children of US-born mothers compared with children of foreign-born 
mothers (3.1 vs. 1.2 per 1,000 person-years; P = 0.05).
By age group, the mortality rate was 3.8 per 1,000 person-years among children 0 to <2 
years old and 1.0 per 1,000 person-years among children 2–9 years old. The highest 
mortality rates were found among infants 0 to <1 year old (4.2 per 1,000 person-years), with 
a median age at death of 3.4 months, and toddlers between 1 and <2 years old (3.3 per 1,000 
person-years), with a median age at death of 17 months. A significant ninefold higher 
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mortality rate was found among LBW infants as compared with those with normal birth 
weight (20.8 vs. 2.3 per 1,000 person-years; P < 0.01); a smaller but nonsignificant 
difference in mortality was observed among toddlers. Similarly, statistically significant 
differences in mortality were observed among preterm children as compared with full-term 
children at ages 0 to <2 years (11.4 vs. 2.8 per 1,000 person-years; P = 0.02) and among 
infants of US-born mothers versus foreign-born mothers (8.4 vs. 1.0 per 1,000 person-years; 
P = 0.03). For the two maternal racial/ethnic groups examined, there was no significant 
difference in mortality rates among children younger than 2 years old. However, children 
ages 2–9 years born to Hispanic mothers had a significantly higher mortality rate as 
compared with those born to non-Hispanic black mothers (3.5 vs. 0.7 per 1,000 person-
years; P = 0.05).
As compared with all-cause mortality from 28 days through 9 years of age for all New York 
births (with or without SCD) during 2000–2008, mortality among children with SCD was 
significantly higher; the rate ratio was 3.6 for all SCD cases and 5.1 for HbSS or HbSβ0 
cases (Table 2). Mortality rate ratios by age group were 1.5, 10.0, and 7.0 at 28 days to 11 
months, 12–23 months, and 2–9 years, respectively. Postneonatal infant (28 days to 11 
months) mortality rates were not significantly higher among children with SCD, but child 
(≥1 year) mortality rates were significantly higher for children with SCD. By SCD type, 
child mortality ratios were significantly higher for HbSS or HbSβ0 cases but not for HbSC 
cases.
Among children born to non-Hispanic black mothers, mortality from 28 days through 9 
years was, significantly, 1.9 times higher for children with SCD as compared with all New 
York children (Table 2). Children with SCD born to Hispanic mothers had a significant 6.1-
fold higher mortality rate as compared with all children of Hispanic mothers. Among 
children with HbSS or HbSβ0 born to non-Hispanic black or Hispanic mothers, the mortality 
ratios were 2.7 and 8.4, respectively, both of which were statistically significant.
LBW children with HbSS or HbSβ0 born to US-born mothers had a significant sevenfold 
higher overall mortality rate as compared with those of foreign-born mothers (18.1 vs. 2.6 
per 1,000 person-years; P = 0.09); the infant mortality rate was 3.7-fold (statistically 
nonsignificantly) higher (56.6 vs. 15.4 per 1,000 person-years; P = 0.33) (Figure 1a). 
Among children with HbSS or HbSβ0 born to US-born mothers, a statistically significant 
9.5-fold higher overall mortality rate was found among LBW (<2,500 g) children as 
compared with normal-birth-weight children (18.1 vs. 1.9 per 1,000 person-years; P < 0.01); 
infant mortality rates were 56.6 and 0.0 per 1,000 person-years, respectively (P < 0.01). No 
differences by maternal race/ethnicity stratified by maternal place of birth were significant 
(Figure 1b).
Twelve of the 21 deaths (57.1%) had SCD listed on the death certificate, and all had HbSS 
or HbSβ0 based on NBS records (Table 3). Among the 12 deaths with SCD listed on the 
death certificate, 2 were likely unrelated to SCD; the cause in one case was listed as 
“noninfective gastroenteritis and colitis” and the other cause was listed as birth asphyxia and 
respiratory arrest. The remaining 10 deaths (47.6%) were presumed to be related to SCD. Of 
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those 10 deaths, 2 had no other cause listed, 4 had respiratory disorders, 2 had sepsis, and 
one each had spleen disease and heart disease listed.
Of the nine deaths (42.9%) for which SCD was not mentioned on the death certificate, four 
had HbSS or HbSβ0 and five had HbSC (Table 3). The most common underlying causes 
were external injury (n = 3) and extreme immaturity (n = 2). The remaining four deaths had 
birth injury, noninfective gastroenteritis and colitis in combination with prematurity, 
congenital anomaly in combination with prematurity, and intussusception listed and were 
not classified as related to SCD. Of the16 deaths among children with HbSS or HbSβ0, 10 
(62.5%) were presumed related to SCD, as noted above. By contrast, all five deaths among 
children with HbSC appeared to be unrelated to SCD. Deaths unrelated to SCD accounted 
for 10 of 14 deaths among children with SCD during the first 2 years of life. None of the 
five deaths before 6 months of age were classified as related to SCD.
DISCUSSION
This study used linked NBS and vital (both birth and death) records to investigate childhood 
mortality for a statewide cohort of children with SCD followed from diagnosis after NBS for 
1–10 years. One previous study from 1998 used linked NBS and death records to evaluate 
SCD-related mortality during the first 3 years of life in three states.32 Other studies either 
followed a birth cohort of children identified through NBS through a tertiary-care center12,14 
or relied on death certificates to ascertain cases of SCD.11,13,15 The linkage with vital 
records also allowed assessment of the association of LBW with infant and child mortality 
among children diagnosed with SCD.
The low mortality rates among young children with SCD born during 2000–2008 in New 
York are consistent with published estimates of national trends in SCD-related pediatric 
mortality.13,15,16 Yanni et al.13 reported a roughly 40% decrease in SCD mortality among 
black children ages 0–3 years between 1995–1998 and 1999–2002, although the 
International Classification of Diseases, 10th revision, codes used for the latter time period 
did not include codes for SCD–β thalassemia. The investigators attributed the decrease in 
large part to the routine administration of pneumococcal conjugate vaccine beginning in 
2000. Similarly, Hamideh and Alvarez15 reported >50% decreases in SCD mortality among 
African-American children <1 and 1–4 years of age between 1989–1998 and 1999–2003, 
although the earlier period included years before the introduction of universal NBS in a 
number of states. Lanzkron et al.16 reported a roughly one-third reduction in all-SCD 
mortality for African-American children <19 years old between 1994–1998 and 1999–2005 
but did not report estimates for younger children.
The Dallas Newborn Cohort, reflecting data for children followed at a single tertiary-care 
center, reported that all-cause mortality during the first 2 years of life (ages <2 years) for 
children with HbSS or HbSβ0 born in 2000–2007 and diagnosed following NBS was 3.2 per 
1,000 person-years.14 In comparison, in the present New York statewide cohort study the 
all-cause mortality rate for children ages 0 to <2 years with HbSS or HbSβ0 born in 2000–
2008 and diagnosed following NBS was 4.4 per 1,000 person-years, one-third higher. At 
ages 2–9 years, mortality rates were 0 (in the study using the Dallas cohort) and 1.4 per 
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1,000 person-years (in the study using the New York cohort). The absolute differences in 
mortality rates were 1.2 per 1,000 person-years during the first 2 years and 1.4 per 1,000 
person-years at ages 2–9 years.
A previous study reported that among black infants born in California and Illinois during 
1990–1994, 1.5% of children with SCD diagnosed after NBS died of any cause by the end 
of 1995; the cumulative mortality rate for all black children born during the same time 
period was 2.0%.32 The present study likewise found that cumulative all-cause mortality 
was lower among children with confirmed SCD born to New York non-Hispanic black 
mothers than among all children born to New York non-Hispanic black mothers during the 
same time period (data not shown). However, when neonatal deaths were excluded to avoid 
bias from undercounting deaths among children with undiagnosed SCD, the results were 
reversed, and all-cause mortality was significantly higher for children with SCD born to 
non-Hispanic black mothers. In particular, deaths were substantially higher among children 
with HbSS or HbSβ0; among children with HbSC, deaths were not significantly increased 
relative to the general population matched by maternal race and ethnicity. The implication is 
that, overall, deaths in early childhood remain significantly higher among children with the 
more severe forms of SCD but not for children with the milder forms.
Twelve of 21 deaths among children identified with SCD through NBS in New York had 
SCD listed on the death certificate as an underlying cause of death. Ten of the 12 (47.6%) 
were SCD-related deaths; all occurred among the 61% (1,173 of 1,911) of children who had 
sickle cell anemia (HbSS or HbSβ0). Children with HbSC or other forms of SCD and who 
died had causes of infant and child mortality similar to those of the general population. 
These results are similar to the findings of the Dallas Newborn Cohort study that 15 of 25 
infant and child deaths (60%) before 2002 were related to SCD, and all 15 of those children 
had HbSS.14
Infant mortality was significantly higher among New York children with diagnosed SCD 
born to US-born mothers as compared with those born to foreign-born mothers. That 
difference appears seems to be unrelated to SCD subtype and race/ethnicity; no subgroup 
differences are statistically significant. Although not statistically significant, five of six 
deaths among children with HbSS or HbSβ0 who had a birth weight <2,500 g occurred 
among children of US-born mothers (Table 1). This could reflect the so-called immigrant 
paradox that black or Hispanic children born to US-born mothers are at higher risk for LBW 
than babies born to foreign-born mothers.33,34 A study from Florida reported that children 
with SCD were roughly 50% more likely to have a birth weight of <2,500 g and roughly 
200% more likely to have a birth weight of <1,500 g.35 Children with SCD and US-born 
mothers may be at the greatest risk for lethal complications of LBW.
Estimates of mortality among children with diagnosed SCD do not capture deaths among 
infants born with SCD who die before diagnosis. Three neonatal deaths were recorded 
among 1,911 infants with a diagnosis of SCD, but 13–17 deaths would be expected, using 
the average neonatal mortality rates of 7 or 8.8 per 1,000 births recorded for infants born to 
nonwhite or black mothers in the United States during 2006, respectively.36 Thus, the true 
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number of infants born with SCD in New York during the study period may have been 1,921 
to 1,925, with 0.5–0.7% missed cases as a result of death before diagnosis.
The exclusion of neonatal deaths occurring before diagnosis following NBS has broader 
ramifications for studies of outcomes for conditions following NBS. Restricting cases to 
children with a confirmed diagnosis excludes infants with the disorder who died before they 
could complete the screening and diagnostic process. No NBS test should be assumed to 
detect 100% of cases, and children who die as neonates are susceptible to not being counted 
among confirmed cases of disease.37
This study has limitations similar to those of the 1998 three-state study32 and other state-
specific analyses of survival. First, deaths that occurred outside of New York are not 
recorded in New York death records. However, a recent study of early childhood mortality 
and survival among Texas children with selected birth defects reported that using the 
National Death Index, which includes all US deaths, to supplement the Texas state death 
certificates identified only 0.7 and 1.5% additional deaths among children with congenital 
heart defects38 and children with heterotaxy syndrome,39 respectively. Second, the inability 
to link some records to death certificates could have resulted in some deaths being missed. 
Third, SCD-related complications may not be recorded on death certificates, and the 
assignment of deaths as SCD related or unrelated is subjective. Fourth, because births 
without a SCD diagnosis were not linked to death records, we were not able to compare 
mortality for children without SCD with that for children with SCD. Fifth, some of the 
stratified analyses in our study have unstable results because of small numbers, and those 
findings need to be interpreted with caution. Sixth, because of small numbers of deaths, we 
were not able to control for potential confounding through multivariable analysis. 
Nonetheless, important study strengths are the validated diagnoses of SCD and population-
based data that provide more comprehensive representativeness of outcomes compared with 
clinic-based studies.
In summary, this statewide population assessment of children in New York affected by SCD 
and born since 2000 indicates that postneonatal (28 days to 9 years) mortality for children 
with HbSS or HbSβ0 remains significantly higher than that for all children of the same ages 
born in New York matched by maternal race/ethnicity. Despite recent progress in reducing 
mortality among young children with SCD,13–16 some children with sickle cell anemia 
(HbSS or HbSβ0) continue to die of complications of SCD.40 To fully realize the promise of 
NBS in preserving lives of children affected by SCD, health strategies must increase the 
promotion of evidence-based disease-modifying therapies, comprehensive regular screening 
for disease-related complications, and parental education; LTFU is needed to assess the use 
of services and outcomes.
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Figure 1. Comparison of mortality rate (per 1,000 person-years (PYs)) among New York 
children born in 2000–2008 with HbSS or HbSβ0 by maternal nativity (US born, foreign born) 
and age group (overall: 0–9 years; infancy: <1 year; post infancy: 1–9 years)
Stratified by (a) birth weight (<2,500 g or ≥2,500 g) and (b) maternal race/ethnicity (non-
Hispanic (NH) white, NH black, Hispanic). *A statistically significant difference was found 
between low birth weight and normal birth weight. N, number of deaths in each category; 
Zero rate, resulted from zero deaths.
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